ClinicalTrials.gg
CompletedNCT00375284Updated Oct 31, 2013

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

A Phase 4 interventional study of Pramipexole in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 52 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-10-31.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
404
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.

Enrollment
Largest of 17
404 · median 154
Started
2006
with 4 others
Phase 4
8 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one has the largest enrollment, is one of 5 that started in 2006, is one of 8 in phase 4, and was the 10th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pramipexole in Restless Legs Syndrome as a file.
02

Study summary

This trial is a 6-week, double-blind, randomized, active and placebo-controlled parallel-group study with a primary objective of comparison of starting doses of pramipexole fixed-dose (0.25 mg daily) and pramipexole titrated-dose (0.125 mg qd for 1 week, then 0.25 mg qd for the remaining 5 weeks) with placebo to evaluate efficacy and safety in treating RLS symptoms in patients diagnosed with idiopathic RLS.

The secondary objectives of this study will be to assess the onset of action of symptomatic relief of RLS for pramipexole with daily assessment of PGI and modified IRLS during two intervals of the first 2 weeks (Days 2, 3 and 4 and Days 9, 10, and 11) and assessment of IRLS, PGI and CGI-I at Weeks 1, 2, 4 and 6 (CGI-I additionally on Day 3).

03

Conditions studied

  • Restless Legs Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written consistent with ICH-GCP and local IRB/IEC requirements obtained prior to any study procedures being performed and the ability and willingness to comply with study treatment regimen and to attend study assessments.
  2. Male or female out-patients 18 to 80 years of age.
  3. Diagnosis of idiopathic RLS according to the clinical RLS criteria revised by the IRLSSG in collaboration with the U.S.A. National Institutes of Health [P03-03355]. All four criteria must be present to fulfil the diagnosis of RLS:

    • An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. (Sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs).

    The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.

    • The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
    • The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present).
  4. RLS symptoms present at least 2 to 3 days per week during the last 3 months.
  5. IRLS rating scale score >15 at baseline (Visit 2).

Exclusion criteria

Exclusion Criteria:

  1. Women of (i.e., premenopausal women, or women less than 6 months after last menses) who do not use during the clinical trial an adequate method of such as: double barrier protection (e.g., diaphragm or condom and spermicide), intrauterine device, hormonal therapy (oral, injectable, or subcutaneous), or partners surgical sterilization.
  2. Any women of child-bearing potential not having negative pregnancy test at screening.
  3. Breastfeeding women.
  4. Concomitant or previous pharmacologic therapy for RLS as follows:

    • Any intake of dopamine agonists within 14 days prior to baseline (Visit 2).
    • Any intake of L-dopa within 14 days prior to baseline (Visit 2).
    • Any intake of L-dopa prior to baseline visit, if augmentation in RLS symptoms was observed.
    • Unsuccessful prior treatment with non-ergot dopamine agonists (e.g., pramipexole, ropinirole).
  5. All treatment less than 14 days before baseline (Visit 2) or concomitant treatment with medication or dietary supplements which could significantly influence RLS symptoms, e.g., dopaminergic (other than levodopa and dopamine agonists) or antidopaminergic drugs, non-selective MAO inhibitors, sympathomimetics, neuroleptics, antidepressants, hypnotics, any benzodiazepines, antiepileptics, opioids, clonidine, ferrous salts, magnesium, folic acid, vitamin B12, antihistaminics, lithium, metoclopramide.
  6. Withdrawal symptoms of any medication must not be present at baseline (Visit 2).
  7. Previous pramipexole non-responders in other indications than RLS.
  8. Patients with known to pramipexole or any other component of the product or placebo tablets.
  9. Confirmed diagnosis of diabetes mellitus requiring insulin therapy.
  10. Any of the following lab results at screening:

    • Patients with any abnormalities in laboratory parameters at screening at the investigators discretion.
    • (Hb) below lower limit of normal (LLN).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
404 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The co-primary endpoints are: Assessment of clinical response of treatment measured by the change from baseline in total IRLS score and CGI-I responder rate (at least much improved) after 6 weeks, 2 weeks and 1 week.

    Time frame: 6 weeks

Secondary outcomes

  1. Onset of action on Day 3 as measured by the CGI-I responder rate Onset of action as measured by PGI and modified IRLS score Clinical Global Impression of improvement Patient Global Impression IRLS as a responder rate VAS score for pain in limbs

    Time frame: 6 weeks

07

Study locations

52 sites
  • 248.616.065 Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • 248.616.028 Boehringer Ingelheim Investigational Site
    Dothan, Alabama, United States
  • 248.616.035 Boehringer Ingelheim Investigational Site
    Mesa, Arizona, United States
  • 248.616.025 Boehringer Ingelheim Investigational Site
    Peoria, Arizona, United States
  • 248.616.073 Boehringer Ingelheim Investigational Site
    Phoenix, Arizona, United States
  • 248.616.067 Boehringer Ingelheim Investigational Site
    Tucson, Arizona, United States
  • 248.616.009 Boehringer Ingelheim Investigational Site
    Fayetteville, Arkansas, United States
  • 248.616.040 Boehringer Ingelheim Investigational Site
    Foothill Ranch, California, United States
  • 248.616.062 Boehringer Ingelheim Investigational Site
    Fullerton, California, United States
  • 248.616.050 Boehringer Ingelheim Investigational Site
    Pasadena, California, United States
  • 248.616.031 Boehringer Ingelheim Investigational Site
    Colorado Springs, Colorado, United States
  • 248.616.017 Boehringer Ingelheim Investigational Site
    Pueblo, Colorado, United States
  • 248.616.071 Boehringer Ingelheim Investigational Site
    Wallingford, Connecticut, United States
  • 248.616.043 Boehringer Ingelheim Investigational Site
    Deland, Florida, United States
  • 248.616.014 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 248.616.020 Boehringer Ingelheim Investigational Site
    Naples, Florida, United States
  • 248.616.048 Boehringer Ingelheim Investigational Site
    Pembroke Pines, Florida, United States
  • 248.616.072 Boehringer Ingelheim Investigational Site
    Spring Hill, Florida, United States
  • 248.616.018 Boehringer Ingelheim Investigational Site
    St. Petersburg, Florida, United States
  • 248.616.049 Boehringer Ingelheim Investigational Site
    Augusta, Georgia, United States
  • 248.616.033 Boehringer Ingelheim Investigational Site
    Columbus, Georgia, United States
  • 248.616.057 Boehringer Ingelheim Investigational Site
    Macon, Georgia, United States
  • 248.616.066 Boehringer Ingelheim Investigational Site
    Savannah, Georgia, United States
  • 248.616.047 Boehringer Ingelheim Investigational Site
    Stockbridge, Georgia, United States
  • 248.616.059 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 248.616.045 Boehringer Ingelheim Investigational Site
    Lenexa, Kansas, United States
  • 248.616.061 Boehringer Ingelheim Investigational Site
    Olathe, Kansas, United States
  • 248.616.060 Boehringer Ingelheim Investigational Site
    Baton Rouge, Louisiana, United States
  • 248.616.058 Boehringer Ingelheim Investigational Site
    Brighton, Massachusetts, United States
  • 248.616.051 Boehringer Ingelheim Investigational Site
    Wellesley Hills, Massachusetts, United States
  • 248.616.001 Boehringer Ingelheim Investigational Site
    Minneapolis, Minnesota, United States
  • 248.616.004 Boehringer Ingelheim Investigational Site
    Jackson, Mississippi, United States
  • 248.616.064 Boehringer Ingelheim Investigational Site
    Florissant, Missouri, United States
  • 248.616.016 Boehringer Ingelheim Investigational Site
    St. Louis, Missouri, United States
  • 248.616.063 Boehringer Ingelheim Investigational Site
    St. Louis, Missouri, United States
  • 248.616.053 Boehringer Ingelheim Investigational Site
    Dover, New Hampshire, United States
  • 248.616.036 Boehringer Ingelheim Investigational Site
    Albuquerque, New Mexico, United States
  • 248.616.021 Boehringer Ingelheim Investigational Site
    Albany, New York, United States
  • 248.616.013 Boehringer Ingelheim Investigational Site
    Cincinnati, Ohio, United States
  • 248.616.003 Boehringer Ingelheim Investigational Site
    Cleveland, Ohio, United States
  • 248.616.068 Boehringer Ingelheim Investigational Site
    Marion, Ohio, United States
  • 248.616.012 Boehringer Ingelheim Investigational Site
    Norman, Oklahoma, United States
  • 248.616.006 Boehringer Ingelheim Investigational Site
    Oklahoma City, Oklahoma, United States
  • 248.616.019 Boehringer Ingelheim Investigational Site
    Oklahoma City, Oklahoma, United States
  • 248.616.069 Boehringer Ingelheim Investigational Site
    Clarks Summit, Pennsylvania, United States
  • 248.616.008 Boehringer Ingelheim Investigational Site
    Columbia, South Carolina, United States
  • 248.616.005 Boehringer Ingelheim Investigational Site
    Dallas, Texas, United States
  • 248.616.070 Boehringer Ingelheim Investigational Site
    Rockwall, Texas, United States
  • 248.616.039 Boehringer Ingelheim Investigational Site
    San Marcos, Texas, United States
  • 248.616.011 Boehringer Ingelheim Investigational Site
    Alexandria, Virginia, United States
  • 248.616.055 Boehringer Ingelheim Investigational Site
    Norfolk, Virginia, United States
  • 248.616.024 Boehringer Ingelheim Investigational Site
    Milwaukee, Wisconsin, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006 and a primary completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2006
First posted
Sep 12, 2006
Start
Sep 2006
Primary completionActual
Jul 2007
Last update
Oct 31, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00375284
First posted
Sep 12, 2006
Start date
Sep 2006
Primary completion
Jul 2007
Last update
Oct 31, 2013

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion